Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, cisplatin, and 5-fluorouracil with or without atezolizumab in metastatic or unresectable squamous cell anal carcinoma
2017-003185-27Phase 2Active
- Sponsor
- GERCOR
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of atezolizumab in anal squamous cell carcinoma (SCCA) (2 arms), sponsored by GERCOR. Primary endpoints: Progression-free survival rate at 12 months and Progression-free survival (PFS). Started Feb 2018; status: active.
02
Drugs
atezolizumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2017-003185-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003185-27.